James J. Harding, MD, on Advanced Biliary Tract Cancer: Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy

October 28, 2026

The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At the ESMO Congress 2026, invited discussant James J. Harding, MD, reviewed the results from the preplanned interim analysis (Abstract LBA8). 

Related Content